Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia

Last updated: March 27, 2017
Sponsor: New York Presbyterian Hospital
Overall Status: Completed

Phase

3

Condition

Cervical Intraepithelial Neoplasia

Cervical Dysplasia

Treatment

N/A

Clinical Study ID

NCT00212381
9218
  • Ages 18-80
  • Female
  • Accepts Healthy Volunteers

Study Summary

To determine if the use of oral Diindolylmethante (DIM), a marketed cruciferous vegetable based dietary supplement (Bioresponse-DIM), is associated with the regression of cervical dysplasia in otherwise healthy women.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Non pregnant women greater than or equal to 18 years of age able to consent

  • CIN II or III confirmed by histology

  • Karnofsky performance status >= 80

  • No prior treatment for dysplasia in the past 4 months

Exclusion

Exclusion Criteria:

  • Incompletely visible lesion

  • Diethylstilbestrol (DES) exposure

  • HIV seropositive

Study Design

Total Participants: 62
Study Start date:
September 01, 2000
Estimated Completion Date:
July 31, 2010

Study Description

To determine if the use of oral Diindolylmethane (DIM), a marketed cruciferous vegetable based dietary supplement (BioResponse-DIM®), is associated with the regression of cervical dysplasia in otherwise healthy women. Additionally, the study aims to see how the use of the BioResponse-DIM supplement correlates with cervical HPV colonization, and to asses the tolerability of daily DIM supplementation

Connect with a study center

  • NYU School of Medicine

    New York, New York 10016
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.